Effect of Extracellular ATP on Cisplatin-Induced Cytotoxicity in Human Ovarian Carcinoma Cells

Rotte, Anand; Garmann, Dirk; Buβ, Irina; Jaehde, Ulrich

doi:10.1159/000287351

Cited by 9 publications

(9 citation statements)

References 67 publications

(67 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Variants of the RB1 gene have been implicated as risk factors for invasive ovarian cancer [429]. A recent study has shown that the presence of ATP during the treatment of human ovarian carcinoma with cisplatin leads to additive cytotoxicity [430].…”

Section: Ovarian Cancermentioning

confidence: 99%

Purinergic signalling and cancer

Burnstock

Virgilio

2013

Purinergic Signalling

266

265

View full text Add to dashboard Cite

Receptors for extracellular nucleotides are widely expressed by mammalian cells. They mediate a large array of responses ranging from growth stimulation to apoptosis, from chemotaxis to cell differentiation and from nociception to cytokine release, as well as neurotransmission. Pharma industry is involved in the development and clinical testing of drugs selectively targeting the different P1 nucleoside and P2 nucleotide receptor subtypes. As described in detail in the present review, P2 receptors are expressed by all tumours, in some cases to a very high level. Activation or inhibition of selected P2 receptor subtypes brings about cancer cell death or growth inhibition. The field has been largely neglected by current research in oncology, yet the evidence presented in this review, most of which is based on in vitro studies, although with a limited amount from in vivo experiments and human studies, warrants further efforts to explore the therapeutic potential of purinoceptor targeting in cancer.

show abstract

Section: Ovarian Cancermentioning

confidence: 99%

Purinergic signalling and cancer

Burnstock

Virgilio

2013

Purinergic Signalling

266

265

View full text Add to dashboard Cite

show abstract

“…This suggested us that cinobufacini could enhance killing effect of osteosarcoma cells when combined with cisplatin, therefore, a greater anti-tumor effect would be triggered if cinabufotalin were used in the chemotherapy. Since there were a great number reports about side effects on digestive, nervous, blood and other body systems due to application of cisplatin during the regular chemotherapy of osteosarcoma patients (Konstantakou et al, 2009;LaPensee et al, 2010;Maroto et al, 2011;Rotte et al, 2010;Sprowl et al, 2012), we suppose ,combination of cinobufacini and cisplatin will avoid all these side effects of chemotherapy, and by this way, cinobufacini will promote from the second-line to the first-line anti-tumor drugs and will play a more important role in osteosarcoma therapy. In addition, our research showed the killing effect by the application of cinobufotalin and cisplatin were fulfilled by inducing apoptosis of osteosarcoma cells which were revealed from the cell morphology (Figure2A-2D), cell apoptosis (Figure2E -2H) and FCM analysis (Figure3A-3B).…”

Section: Discussionmentioning

confidence: 99%

Efficient Killing Effect of Osteosarcoma Cells by Cinobufacini and Cisplatin in Combination

Huang¹,

Gong²,

Li³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Purpose: To study the killing effects on osteosarcoma cells of cinobufacini and cisplatin in combination and the related mechanisms so as to explore the chemotherapeutic method with integrated traditional Chinese and Western medicines. Methods: Cinobufacini and cisplatin were applied to OS732 cells singly or jointly and survival rates were measured by MTT assay. Changes in cellular shape were observed with inverted phase contrast and fluorescence microscopy and apoptosis rates were analyzed with flow cytometry (FCM). Immunocytochemistry were used to examine the Fas expression of OS732 cells. Results: The combination of cinobufacini and cisplatin had the effect of up-regulating Fas expression and inducing apoptosis. The survival rate of combined application of 100 µg/ml cinobufacini and 1 µg/ml cisplatin on OS-732 cells was significantly lower than with either of the agents alone (p<0.01). Changes in cellular shape and apoptotic rates also indicated the apoptosis-inducing effects of combined application were much enhanced. Conclusion: The combination of cinobufacini and cisplatin demonstrated strong killing effects on OS-732 cells which might be related to up-regulation of Fas expression.

show abstract

“…However, the recurrences in those patients who were found with stable or progressive RCB after IDS were mainly drug-resistant recurrences, so the chemotherapy plans may be changed after IDS. In order to improve prognosis after IDS, fresh tissue or cells may be used to assay drug resistance in vitro to help make individual chemotherapy decisions [23]. For patients with clinical benefit as evaluated by serum CA-125, whose RCB decreased no more than 50%, the recurrence type may be of the sensitive or partially platinum-sensitive type.…”

Section: Discussionmentioning

confidence: 99%

The Changes in Residual Cancer Burden after Interval Debulking Surgery Are Effective in Evaluating the Response to Adjuvant Chemotherapy

Kong

et al. 2011

Chemotherapy

View full text Add to dashboard Cite

Objective: To study the clinical significance of the change of residual cancer burden (RCB) of epithelial ovarian carcinoma (EOC) between primary (PDS) and interval debulking surgery (IDS) in order to evaluate the effectiveness of adjuvant chemotherapy. Methods: Thirty-eight EOC patients with suboptimal PDS with adjuvant chemotherapy were selected for this retrospective study and divided into pathologically negative (group A) and pathologically positive (group B) groups based on the histopathological examination and the change of size of residual disease after IDS. Patients in group B were further divided into groups B1 (partial remission criteria, n = 9), B2 (consistent with stable disease, n = 12) and B3 (consistent with disease progression, n = 4) based on the changes in RCB between PDS and IDS and the guidelines to evaluate the response to treatment in solid tumors (Response Evaluation Criteria in Solid Tumors, RECIST). The responses to chemotherapy evaluated by pathological examination of RCB versus by CA-125, recurrence patterns, and prognoses were analyzed. Results: The clinical benefit rates evaluated by pathological assessment for groups A, B1, B2 and B3 were 100, 100, 100 and 0%, respectively (p < 0.01), whereas the rates were not statistically different when evaluated by CA-125 (100, 100, 91.7 and 100%, respectively; p > 0.05). The median progression-free survival (PFS) for patients in groups A and B was 36 and 6 months, respectively (p < 0.05); the median overall survival (OS) was 93 and 42 months, respectively (p < 0.05). There were no significant differences in median PFS or OS among patients in groups B1, B2 and B3 (PFS: 16, 6 and 1.5 months; OS: 52, 31 and 30.5 months, respectively; all p > 0.05), but there were significant differences in median PFS or OS between B1 and B3. There was no significant difference in recurrence rates between groups A and B (53.8 vs. 72.0%, p > 0.05), but there were significant differences in the rate of drug-resistant recurrence [28.6% (2/7) vs. 72.2% (13/18), p < 0.05] and in median PFS of relapsed patients (19 vs. 4 months, p < 0.05). Conclusion: The histopathological assessment of RCB between PDS and IDS may be used to evaluate and predict the response to adjuvant chemotherapy in EOC.

show abstract

Effect of Extracellular ATP on Cisplatin-Induced Cytotoxicity in Human Ovarian Carcinoma Cells

Cited by 9 publications

References 67 publications

Purinergic signalling and cancer

Purinergic signalling and cancer

Efficient Killing Effect of Osteosarcoma Cells by Cinobufacini and Cisplatin in Combination

The Changes in Residual Cancer Burden after Interval Debulking Surgery Are Effective in Evaluating the Response to Adjuvant Chemotherapy

Contact Info

Product

Resources

About